ITMI20040069A1 - Uso di composizioni di acidi grassi n-3 ad elevata concentrazione per il trattamento di disturbi del sistema nervoso centrale - Google Patents

Uso di composizioni di acidi grassi n-3 ad elevata concentrazione per il trattamento di disturbi del sistema nervoso centrale

Info

Publication number
ITMI20040069A1
ITMI20040069A1 IT000069A ITMI20040069A ITMI20040069A1 IT MI20040069 A1 ITMI20040069 A1 IT MI20040069A1 IT 000069 A IT000069 A IT 000069A IT MI20040069 A ITMI20040069 A IT MI20040069A IT MI20040069 A1 ITMI20040069 A1 IT MI20040069A1
Authority
IT
Italy
Prior art keywords
disorders
treatment
fatty acid
nervous system
high concentration
Prior art date
Application number
IT000069A
Other languages
English (en)
Inventor
Tiberio Bruzzese
Original Assignee
Tiberio Bruzzese
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34803698&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ITMI20040069(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Tiberio Bruzzese filed Critical Tiberio Bruzzese
Priority to IT000069A priority Critical patent/ITMI20040069A1/it
Publication of ITMI20040069A1 publication Critical patent/ITMI20040069A1/it
Priority to PCT/EP2005/000522 priority patent/WO2005070411A1/en
Priority to PT05701068T priority patent/PT1706106E/pt
Priority to JP2006550032A priority patent/JP5087280B2/ja
Priority to RSP-2009/0437A priority patent/RS51195B/sr
Priority to DE602005015415T priority patent/DE602005015415D1/de
Priority to US10/586,863 priority patent/US8829048B2/en
Priority to ES05701068T priority patent/ES2329809T3/es
Priority to PL05701068T priority patent/PL1706106T3/pl
Priority to DK05701068T priority patent/DK1706106T3/da
Priority to EP05701068A priority patent/EP1706106B9/en
Priority to HR20090550T priority patent/HRP20090550T1/hr
Priority to US14/451,606 priority patent/US20140343143A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IT000069A 2004-01-21 2004-01-21 Uso di composizioni di acidi grassi n-3 ad elevata concentrazione per il trattamento di disturbi del sistema nervoso centrale ITMI20040069A1 (it)

Priority Applications (13)

Application Number Priority Date Filing Date Title
IT000069A ITMI20040069A1 (it) 2004-01-21 2004-01-21 Uso di composizioni di acidi grassi n-3 ad elevata concentrazione per il trattamento di disturbi del sistema nervoso centrale
EP05701068A EP1706106B9 (en) 2004-01-21 2005-01-20 Use of highly concentrated compositions of selected n-3 fatty acids for the treatment of central nervous system disturbances
DK05701068T DK1706106T3 (da) 2004-01-21 2005-01-20 Anvendelse af höjkoncentrerede sammensætninger af udvalgte n-3-fedtsyrer til behandling af forstyrrelser i centralnervesystemet
DE602005015415T DE602005015415D1 (de) 2004-01-21 2005-01-20 N ausgewählter n-3-fettsäuren zur behandlung von erkrankungen des zentralen nervensystems
PT05701068T PT1706106E (pt) 2004-01-21 2005-01-20 Utilização de composições altamente concentradas de ácidos gordos n-3 seleccionados para o tratamento de perturbações do sistema nervoso central
JP2006550032A JP5087280B2 (ja) 2004-01-21 2005-01-20 中枢神経系障害の治療のための、選択されたｎ−３系脂肪酸の高度濃縮組成物の使用
RSP-2009/0437A RS51195B (sr) 2004-01-21 2005-01-20 Upotreba visoko koncentrovanih kompozicija odabranih n-3-masnih kiselina za lečenje poremećaja centralnog nervnog sistema
PCT/EP2005/000522 WO2005070411A1 (en) 2004-01-21 2005-01-20 USE OF HIGHLY CONCENTRATED COMPOSITIONS OF SELECTED n-3 FATTY ACIDS FOR THE TREATMENT OF CENTRAL NERVOUS SYSTEM DISTURBANCES
US10/586,863 US8829048B2 (en) 2004-01-21 2005-01-20 Use of highly concentrated compositions of selected n-3 fatty acids for the treatment of central nervous system disturbances
ES05701068T ES2329809T3 (es) 2004-01-21 2005-01-20 Uso de composiciones muy concentradas de acidos grasos n-3 seleccionados para el tratamiento de transtornos del sistema nervioso central.
PL05701068T PL1706106T3 (pl) 2004-01-21 2005-01-20 Zastosowanie wysoko stężonych kompozycji wybranych kwasów tłuszczowych n-3 do leczenia zaburzeń ośrodkowego układu nerwowego
HR20090550T HRP20090550T1 (hr) 2004-01-21 2009-10-15 UPOTREBA VISOKO KONCENTRIRANIH PRIPRAVAKA ODABRANIH n-3 MASNIH KISELINA U LIJEČENJU POREMEĆAJA SREDIŠNJEG ŽIVČANOG SUSTAVA
US14/451,606 US20140343143A1 (en) 2004-01-21 2014-08-05 Use of highly concentrated compositions of selected n-3 fatty acids for the treatment of central nervous system disturbances

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IT000069A ITMI20040069A1 (it) 2004-01-21 2004-01-21 Uso di composizioni di acidi grassi n-3 ad elevata concentrazione per il trattamento di disturbi del sistema nervoso centrale

Publications (1)

Publication Number Publication Date
ITMI20040069A1 true ITMI20040069A1 (it) 2004-04-21

Family

ID=34803698

Family Applications (1)

Application Number Title Priority Date Filing Date
IT000069A ITMI20040069A1 (it) 2004-01-21 2004-01-21 Uso di composizioni di acidi grassi n-3 ad elevata concentrazione per il trattamento di disturbi del sistema nervoso centrale

Country Status (12)

Country Link
US (1) US8829048B2 (it)
EP (1) EP1706106B9 (it)
JP (1) JP5087280B2 (it)
DE (1) DE602005015415D1 (it)
DK (1) DK1706106T3 (it)
ES (1) ES2329809T3 (it)
HR (1) HRP20090550T1 (it)
IT (1) ITMI20040069A1 (it)
PL (1) PL1706106T3 (it)
PT (1) PT1706106E (it)
RS (1) RS51195B (it)
WO (1) WO2005070411A1 (it)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8252742B2 (en) * 2004-12-30 2012-08-28 Hill's Pet Nutrition, Inc. Methods for enhancing the quality of life of a senior animal
US8324276B2 (en) 2005-01-24 2012-12-04 Pronova Biopharma Norge As Fatty acid composition for treatment of alzheimer's disease and cognitive dysfunction
EP1772146A1 (en) * 2005-10-03 2007-04-11 Neuropharma, S.A. Polyunsaturated fatty acids as bace inhibitors
EP2364701A1 (en) 2005-12-20 2011-09-14 Cenestra, Llc Omega-3 fatty acid formulations
MX2008008171A (es) 2005-12-21 2008-11-12 Brudy Technology S L Uso de dha epa o epa derivado de dha para tratamiento de una patologia asociada al daño celular oxidante.
ES2277557B1 (es) 2005-12-21 2008-07-01 Proyecto Empresarial Brudy, S.L. Utilizacion de acido docosahexaenoico para el tratamiento del daño celular oxidativo.
US8697138B2 (en) 2007-03-28 2014-04-15 Aker Biomarine As Methods of using krill oil to treat risk factors for cardiovascular, metabolic, and inflammatory disorders
EP2612672A1 (en) 2007-03-28 2013-07-10 Aker BioMarine AS Bioeffective krill oil compositions
US8343753B2 (en) 2007-11-01 2013-01-01 Wake Forest University School Of Medicine Compositions, methods, and kits for polyunsaturated fatty acids from microalgae
AU2015203289B2 (en) * 2008-09-09 2017-03-16 Orygen Research Centre Prevention of psychotic disorders and/or treatment of psychotic symptoms
CA2773031C (en) 2008-09-09 2021-03-02 Orygen Youth Health Research Centre Prevention of psychotic disorders and/or treatment of psychotic symptoms
US8372812B2 (en) 2009-02-26 2013-02-12 Aker Biomarine Asa Phospholipid and protein tablets
WO2012083034A1 (en) * 2010-12-15 2012-06-21 Louis Sanfilippo Modulation of neurotrophic factors by omega-3 fatty acid formulations
AU2014203179C1 (en) 2013-06-14 2017-05-04 Aker Biomarine Antarctic As Lipid extraction processes
GB201400431D0 (en) 2014-01-10 2014-02-26 Aker Biomarine As Phospholipid compositions and their preparation
RU2718983C2 (ru) 2015-02-11 2020-04-15 Акер Биомарин Антарктик Ас Композиции липидов
WO2016128830A1 (en) 2015-02-11 2016-08-18 Aker Biomarine Antarctic As Lipid extraction processes
EP3586640A1 (en) 2018-06-21 2020-01-01 Nuseed Pty Ltd Dha enriched polyunsaturated fatty acid compositions
PL238670B1 (pl) * 2018-07-06 2021-09-20 Skotan Spolka Akcyjna Sposób otrzymywania oczyszczonej kompozycji estrów kwasów tłuszczowych i kompozycja estrów kwasów tłuszczowych
WO2022050355A1 (ja) * 2020-09-04 2022-03-10 国立大学法人千葉大学 ドコサヘキサエン酸、ドコサヘキサエノイル基含有ホスファチジン酸、又はその誘導体によるセロトニントランスポーター関連精神疾患の予防・治療剤

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1239587A (en) 1983-10-24 1988-07-26 David Rubin Combined fatty acid composition for lowering blood cholestrol and triglyceride levels
GB8601915D0 (en) 1986-01-27 1986-03-05 Efamol Ltd Pharmaceutical compositions
IT1205043B (it) * 1987-05-28 1989-03-10 Innova Di Ridolfi Flora & C S Procedimento per l'estrazione di esteri di acidi grassi poliinsaturi da olii di pesce e composizioni farmaceutiche e dietetiche contenenti detti esteri
DE3739700A1 (de) 1987-11-24 1989-06-08 Guenther Dr Med Jeschke Alpha-linolensaeure (18:3,omega 3) und/oder deren derivate enthaltende formulierungen, sowie verfahren zu ihrer herstellung und anwendung in ernaehrung und medizin
JP2524217B2 (ja) 1988-04-18 1996-08-14 マルハ株式会社 脳機能改善組成物、学習能力増強剤、記憶力増強剤、痴呆予防剤または痴呆治療剤
GB2218904A (en) 1988-05-27 1989-11-29 Renafield Limited Pharmaceutical composition based on high-concentration esters of docosahexaenoic acid
GB2218984B (en) * 1988-05-27 1992-09-23 Renafield Limited Process for preparing high-concentration mixtures of polyunsaturated fatty acids & their esters and their prophylactic or therapeutic uses
GB8813766D0 (en) * 1988-06-10 1988-07-13 Efamol Holdings Essential fatty acid compositions
GB8819110D0 (en) 1988-08-11 1988-09-14 Norsk Hydro As Antihypertensive drug & method for production
FR2688145B1 (fr) 1992-03-06 1994-09-23 Borden France Sa Procede et installation pour separer un effluent sous forme de vapeur d'un courant de gaz vecteur.
JPH0672868A (ja) * 1992-08-26 1994-03-15 Maruha Corp 抗精神病薬
GB9224809D0 (en) * 1992-11-26 1993-01-13 Scotia Holdings Plc Schizophrenia
IT1274734B (it) * 1994-08-25 1997-07-24 Prospa Bv Composizioni farmaceutiche contenenti acidi grassi poliinsaturi, loro esteri o sali, unitamente a vitamine o provitamine antiossidanti
SK285210B6 (sk) * 1996-10-11 2006-09-07 Scarista Limited Farmaceutický prípravok na liečenie schizofrénie a použitie oleja obsahujúceho kyselinu eikozapentaenovú alebo stearidonovú, alebo ich kombináciu na prípravu tohto liečiva
GB9901809D0 (en) * 1999-01-27 1999-03-17 Scarista Limited Highly purified ethgyl epa and other epa derivatives for psychiatric and neurological disorderes
GB9916536D0 (en) 1999-07-14 1999-09-15 Scarista Limited Nutritional or pharmaceutical compositions
ATE305810T1 (de) 2000-05-22 2005-10-15 Pro Aparts Investimentos E Con Fettsäure enthaltende pharmazeutische zusammensetzung die wenigstens 80 gew. epa und dha enthält
IT1320180B1 (it) 2000-12-29 2003-11-26 Hunza Di Marazzita Maria Carme Preparazioni nutrizionali e terapeutiche dotate di attivita'antiossidante ed in grado di controllare gli eccessi ponderali e
US6759435B1 (en) * 2003-07-03 2004-07-06 A.P. Group Inc. Antidepressant drugs and methods

Also Published As

Publication number Publication date
PL1706106T3 (pl) 2009-12-31
WO2005070411A1 (en) 2005-08-04
HRP20090550T1 (hr) 2010-01-31
EP1706106B9 (en) 2009-09-16
DE602005015415D1 (de) 2009-08-27
ES2329809T3 (es) 2009-12-01
US8829048B2 (en) 2014-09-09
EP1706106B1 (en) 2009-07-15
PT1706106E (pt) 2009-09-04
US20070161705A1 (en) 2007-07-12
JP5087280B2 (ja) 2012-12-05
RS51195B (sr) 2010-10-31
DK1706106T3 (da) 2009-10-12
JP2007518764A (ja) 2007-07-12
EP1706106A1 (en) 2006-10-04

Similar Documents

Publication Publication Date Title
ITMI20040069A1 (it) Uso di composizioni di acidi grassi n-3 ad elevata concentrazione per il trattamento di disturbi del sistema nervoso centrale
UY31664A1 (es) "aril-hidroxietilamino-pirimidinas y triazinas como moduladores de la amidohidrolasa de ácidos grasos"
UY38953A (es) Amidas de 4-aril-1,4-dihidro-1,6-naftiridina sustituidas y composiciones farmacéu-ticas que las contienen
CR20120389A (es) COMPUESTOS SUSTITUIDOS DE N-(1H-INDAZOL-4-IL)IMIDAZO[1,2-a] PIRIDIN-3-CARBOXAMIDA COMO INHIBIDORES DE cFMS
HN2006013804A (es) Heteroalrilamidas[3.1.0]biciclicas como inhibidores del trasporte de glicina de tipo i
ITMI20020756A0 (it) Composizioni farmaceutiche topiche per il trattamento delle dermatiti
EP1893756A4 (en) ELIMINATION OF N-GLYCOLYLNEURAMINIC ACID FROM MAMMALIAN PRODUCTS FOR HUMAN USE
MA35903B1 (fr) Nouveaux derives d'indolizine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
DE502004008604D1 (de) Pyrrolopyridin-substitutierte benzol-derivate zur behandlung kardiovaskulärer erkrankungen
CY1109587T1 (el) Μεθοδος κατασκευης για κοκκους που περιεχουν εντακαπονη για στοματικες μορφες δοσολογιας
ZA200610055B (en) Chemical compounds and pharmaceutical compositions containing them for the treatment of inflammatory disorders
WO2007061862A3 (en) 2-keto-oxazoles as modulators of fatty acid amide hydrolase
CL2011002231A1 (es) Forma cristalina vi de la agomelatina; proceso de preparacion; composicion farmaceutica; y su uso para tratar estres, ansiedad, trastornos del sueño, enfermedades cardiovasculares, esquizofrenia, fobia, depresion, enfermedades del sistema digestivo.
AR077144A1 (es) Derivado de fenilimidazol como inhibidor de la enzima pde10a, composiciones farmaceuticas y uso de los mismos en el tratamiento de trastornos neurodegenerativos y psiquiatricos
IL190710A0 (en) Diuretic-like compound analogs and pharmaceutical compositions for regulation of central nervous system disorders containing the same
SMT201700105B (it) Nuove composizioni per prevenire e/o trattare disturbi degenerativi del sistema nervoso centrale
ITMI20031311A0 (it) Formulazioni per il trattamento di disturbi artrosici
ITMI20072315A1 (it) Composizioni orali per la prevenzione e il trattamento dei disturbi del colon su base infiammatoria
DK1841433T3 (da) Præparat til behandling af lidelser i centralnervesystemet
ATE439347T1 (de) 7-(2h-pyrazol-3-yl)-3,5-dihydroxy-heptansäure- derivate als hmg-co-a-reductase-inhibitoren zur behandlung von lipidemia
BRPI0909628A2 (pt) compostos de azaindol para o tratamento de distúrbios do sistema nervosos central
ITMI20051231A1 (it) Formulazioni farmaceutiche contenenti colostro e calcio folinato per il trattamento delle affezioni del cavo orale
HK1216993A1 (zh) 用於治療中樞神經系統疾病的含有低濃度唾液酸的重組人紅細胞生成素的鼻用製劑
UY29078A1 (es) Amidas del ácido 5 y 6-aminoalquil indol-2-carboxílico 3-sustituidas y análogos relacionados como inhibidores de la caseína cinasa ie(epsilon)
IT1390968B1 (it) Frazione glicolipidica di cianobatterio per il trattamento delle affezioni del cavo orale